Observational studyEuropean journal of neurology2025
PACAP-38 in Cluster Headache: A Prospective, Case-Control Study of a Potential Treatment Target.
Observational study in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PACAP-38 in Cluster Headache: A Prospective, Case-Control Study of a Potential Treatment Target.European journal of neurology · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundEstimates of pituitary adenylate cyclase-activating peptide-38's (PACAP-38) activity in cluster headache are sparse. We investigated whether plasma levels of PACAP-38 differ between disease states (i.e., bout, remission, chronic) and compared to headache-free controls. Secondly, we assessed a possible correlation between plasma levels of PACAP-38 and Calcitonin gene-related peptide (CGRP).
methodsIn an observational case-control setup, prospectively collected interictal plasma samples from participants in the Danish Cluster Headache Biobank were analyzed for plasma levels of PACAP-38 and CGRP. All participants had blood samples drawn; once if chronic cluster headache or controls, and twice if episodic cluster headache (in bout and in remission phase). Plasma levels were measured with validated immunoassays.
resultsPlasma was derived from 205 patients with cluster headache according to ICHD-3 criteria and 101 sex- and age-matched headache-free controls. PACAP-38 plasma levels were significantly higher in all three disease states of cluster headache: compared to controls, they collectively had a 34.3% (95% CI: 20%-49%, p < 0.0001) higher mean PACAP-38 level. Chronic cluster headache showed the greatest difference by 49.8% (95% CI: 26.7-77.2, p < 0.0001) higher PACAP-38 levels, while episodic cluster headache in bout and remission showed respectively 39.5% (95% CI: 18.8-63.8, p < 0.0001) and 34.1% (95% CI: 14.2-57.5, p = 0.0005) higher plasma levels. No correlation between plasma levels of PACAP-38 and CGRP was demonstrated (Spearmans r = 0.08, p = 0.10).
conclusionsThis large-scale study demonstrated increased PACAP-38 levels in all disease states of cluster headache compared to headache-free controls, strengthening the hope of a possible effect of PACAP-38 targeting treatments in future trials. The lacking correlation between PACAP-38 and CGRP levels should be interpreted with caution and needs to be investigated in future studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.